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Abstract
Introduction The TP53-binding protein (53BP1) has been
shown to influence TP53-mediated transcriptional activation,
thus playing a pivotal role in DNA damage signalling. Genetic
aberrations in TP53 and in ATM and CHEK2 predispose to
cancer. We have therefore examined the effects of 53BP1
single nucleotide polymorphisms (D353E, G412S, and
K1136Q) and the novel 53BP1  6bp deletion
(1347_1352delTATCCC) on breast cancer risk.
Methods Allelic discrimination was performed to investigate the
frequencies of 53BP1 D353E, G412S, and K1136Q and of
1347_1352delTATCCC in 353 patients with breast cancer and
960 control individuals.
Results No significant association of 53BP1 D353E, G412S,
or K1136Q with breast cancer risk was detected. 53BP1
1347_1352delTATCCC, leading to the loss of an isoleucine
and a proline residue, showed a nonsignificant inverse
association with breast cancer risk (odds ratio = 0.61, 95%
confidence interval = 0.22 to 1.68, P = 0.34).
Conclusion The lack of association casts doubt on the putative
effects of D353E, G412S, and K1136Q on breast cancer risk.
Investigating a larger study cohort might elucidate the influence
of the 6bp deletion 1347_1352delTATCCC. Studying the
functional effect and the impact of this variant on the risk of other
cancers may be revealing.
Introduction
The TP53-binding protein (53BP1), a conserved nuclear pro-
tein, was initially identified to interact with the DNA-binding
domain of TP53, thus enhancing TP53-mediated transcrip-
tional activation [1,2]. In response to exogenous exposure to
ionising radiation, 53BP1 becomes hyperphosphorylated and
rapidly localises to sites of DNA double-strand breaks, demon-
strating its determining role in DNA damage signalling [3,4].
53BP1-deficient mice exhibit growth retardation, high radia-
tion sensitivity, and tumour development – features that are
indicative of a defective DNA damage response [5]. 53BP1 is
involved in the phosphorylation of various ataxia telangiectasia
mutated protein (ATM) substrates such as cell cycle check-
point kinase 2 (CHEK2) [3,6]. Mutations in ATM, CKEK2, and
its substrate, TP53, have been shown to predispose to cancer
[6-9]. Therefore, we selected 53BP1 as an attractive candi-
date gene for breast cancer susceptibility.
This is the first study to investigate the effects of the 53BP1
single nucleotide polymorphisms (SNPs) D353E (1059C>G),
G412S (1234G>A), and K1136Q (3406A>C) on breast can-
cer risk, analysing 353 German patients with breast cancer
and 960 controls. 53BP1 D353E, G412S, and K1136Q
showed no association with breast cancer risk. In addition, we
detected a novel, very rare 53BP1  6bp deletion
(1347_1352delTATCCC) showing an inverse association
53BP1 = TP53 binding protein; ATM = ataxia telangiectasia mutated protein; bp = base pairs; CHEK2 = cell cycle checkpoint kinase 2; CI = confi-
dence interval; OR = odds ratio; PCR = polymerase chain reaction; SNP = single nucleotide polymorphism.Breast Cancer Research    Vol 7 No 4    Frank et al.
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with breast cancer risk (age-adjusted odds ratio (OR) = 0.61,
95% confidence interval (CI) = 0.22 to 1.68), lacking signifi-
cance (P = 0.34).
Materials and methods
SNP verification
A randomly chosen set of 23 German patients with familial
breast cancer was initially screened for annotated 53BP1
SNPs (dbSNP database; NCBI (National Center for Biotech-
nology Information)) by DNA sequencing. Sequencing primers
are available upon request. The initial analysis included 53BP1
exons 9, 11, and 17, harbouring three reported nonsynony-
mous polymorphisms (D353E: rs560191; G412S: rs689647;
and K1136Q: rs2602141). When sequencing exon 11, we
additionally detected the 6bp deletion
1347_1352delTATCCC. All validated variants were chosen
for further analyses using a large cohort of breast cancer
patients.
Subjects
The breast cancer patients were 353 unrelated German
women (mean age 44.8 years, range 21 to 80 years) who
were negative for BRCA1 and BRCA2 mutations. In accord-
ance with the German Consortium for Hereditary Breast and
Ovarian Cancer, they were classified into six categories based
on family history: (A1) families with two or more breast cancer
cases including two cases with onset below the age of 50
(39.3% of analysed cases); (A2) families with at least one male
breast cancer case (0.9%); (B) families with at least one
breast cancer and one ovarian cancer case (16.2%); (C) fam-
ilies with at least two breast cancer cases including one case
diagnosed before the age of 50 (33.5%); (D) families with at
least two breast cancer cases comprising two cases diag-
nosed after the age of 50 (5.5%); (E) single cases of breast
cancer diagnosed before the age of 35 (4.6%) [10]. They
were collected during the years 1997 to 2004 through the
Institute of Human Genetics (Heidelberg, Germany) and the
Department of Gynaecology and Obstetrics (Cologne, Ger-
many). The control series included 960 blood donors (mean
age 30.5 years, range 18 to 67 years) collected by the Insti-
tute of Transfusion Medicine and Immunology (Mannheim,
Germany) having the same ethnic background as the breast
cancer patients. Both study populations have been described
earlier [11]. The study was approved by the Ethics Committee
of the University of Heidelberg (Heidelberg, Germany).
PCR amplification and sequencing were performed as previ-
ously described [11]. Conditions are available on request.
Genotyping
53BP1 polymorphisms D353E, G412S, and K1136Q were
analysed using TaqMan allelic discrimination. TaqMan assays
were performed in a reaction volume of 10 µl comprising 5ng
of genomic DNA, each probe at 50 nM, each primer at 225
nM, and 1× Universal Master Mix with the following amplifica-
tion conditions: 2 min at 50°C, 10 min at 95°C and 35 to 45
cycles at 92°C for 15 s and 60°C for 1 min. Amplification prod-
ucts were measured and analysed with the ABI Prism 7900
HT sequence detection system and the SDS software (version
1.2; Applied Biosystems, Foster City, CA, USA). TaqMan
probes and primers were provided by the assay-on-demand
and assay-by-design services, respectively (Applied Biosys-
tems). 53BP1 1347_1352delTATCCC was analysed using
the MGB Eclipse™ Probe System by Epoch Biosciences
(Bothell, WA, USA). Allelic discrimination was carried out as
recommended by the manufacturers using the following
probes: D353E: assay-on-demand C_2944794_10; G412S:
VIC-ACTTCAAAGTGGTGAACC, FAM-AACTTCAAAG-
TAGTGAACC; K1136Q: VIC-GGAGTACTAATAAGGAAA,
FAM-CGGAGTACTAATCAGGAAA;
1347_1352delTATCCC: FAM-CACTTCATCCCAT; TET-
CACTTCCTATCCCATC. Primers and probes were designed
based on GenBank NM_005657 (NCBI) and are available on
request. More than 5% of the genotyping results were con-
firmed by sequencing, and genotype distributions were con-
sistent with Hardy–Weinberg equilibrium.
Statistical methods
Calculations of Hardy–Weinberg equilibrium, genotype-spe-
cific OR, and 95% CI were carried out using a tool offered by
the Institute of Human Genetics, Technical University Munich,
Munich, Germany [12]. Age-adjusted ORs and corresponding
95% CIs were computed by means of unconditional logistic
regression using SAS (Version 8.2; SAS Institute Inc, Cary,
NC, USA). Haplotypes were assigned to subjects using the
SNPHAP software (see [13]), which also reports the posterior
probability of the most likely assignment [14,15].
Results and discussion
Inactivation of ATM and ATM substrates such as CHEK2 have
been shown to predispose to cancer in humans [7]. Along with
ATM and CHEK2, 53BP1 is involved in DNA damage
response and tumour suppression. Recent studies have
shown that 53BP1 and ATM interact in irradiated cells, sug-
gesting that ATM activation is the consequence of the recruit-
ment of ATM to sites of DNA double-strand breaks by 53BP1
[7,9]. Thus, polymorphic variants in 53BP1 are excellent can-
didates for cancer susceptibility. We investigated the impact
of three nonsynonymous amino acid exchanges in 53BP1 on
breast cancer risk. 53BP1 G413S and K1136Q represented
promising candidate SNPs, resulting in the replacement of a
nonpolar by a polar amino acid. Genotype frequencies of the
three 53BP1 polymorphisms between breast cancer cases
and control samples were similar, showing no significant asso-
ciation with breast cancer risk (D353E: age-adusted OR =
1.07, 95% CI = 0.81 to 1.43, P = 0.62; G412S: age-adjusted
OR = 1.22, 95% CI = 0.86 to 1.74, P = 0.26; K1136Q: age-
adjusted OR = 1.10, 95% CI = 0.82 to 1.47, P = 0.53; Table
1). Aditionally, we detected a novel 53BP1 6 bp deletion,
1347_1352delTATCCC, leading to the loss of an isoleucineAvailable online http://breast-cancer-research.com/content/7/4/R502
R504
Table 1
Genotype frequencies of 53BP1 polymorphisms in breast cancer patients and controls
Polymorphism No. (%) of cases No. (%) of controls AOR (95% CI) P
D353E (1059C>G)
CC 165 (48.1) 453 (47.6)
GC 148 (43.1) 405 (42.5)
GG 30 (8.7) 94 (9.9)
Σ 343 952
CC vs GC+GG 1.07 (0.81–1.43) 0.62
G412S (1234G>A)
GG 269 (78.7) 760 (80.1)
AG 67 (19.6) 174 (18.3)
AA 6 (1.8) 15 (1.6)
Σ 342 949
AA+AG vs GG 1.22 (0.86–1.74) 0.26
1347_1352delTATCCC
wt/wt 334 (98.2) 931 (97.4)
delTATCCC/wt 6 (1.8) 25 (2.6)
delTATCCC/delTATCCC 0 (0.0) 0 (0.0)
Σ 340 956
delTATCCC/wt vs wt/wt 0.61 (0.22–1.68) 0.34
K1136Q (3406A>C)
AA 158 (47.4) 448 (47.8)
CA 144 (43.2) 396 (42.2)
CC 31 (9.3) 94 (10.0)
Σ 333 938
CC+CA vs AA 1.10 (0.82–1.47) 0.53
AOR, age-adjusted odds ratio; CI, confidence interval; wt, wild type.
Table 2
Haplotype distribution of 53BP1 polymorphismsa in breast cancer patients and control individuals
Cases Controls ORb 95 % CI P
Haplotype 
1059C>G-1234G
>A-1347_1352-/+-3406A>C
No. (%) Mean posterior
probability
No. (%) Mean posterior
probability
CG+A 444 (68.1) 1 1242 (67.5) 1 1 - -
CG+C 2 (0.3) 1 1 (0.1) 1 n.a. n.a. n.a.
CG–A 6 (0.9) 0.90 25 (1.4) 0.99 0.63 0.23–1.75 0.38
GG+A 1 (0.2) 1 1 (0.1) 1 n.a. n.a. n.a.
GG+C 125 (19.2) 1 376 (20.4) 1 1.02 0.79–1.33 0.86
GA+C 74 (11.3) 1 195 (10.6) 1 1.15 0.83–1.61 0.41
aPolymorphisms D353E (1059C>G), G412S (1234G>A), 1347_1352delTATCCC, and K1136Q (3406A>C). b1059C-1234G-1347_1352+-
3406A as reference. CI, confidence interval; n.a., not available; OR, odds ratio.Breast Cancer Research    Vol 7 No 4    Frank et al.
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and a proline residue at positions 450 and 451, which has not
been described previously. Comparing the occurrence of this
rare, 6 bp deletion between cases and controls revealed an
inverse association with breast cancer risk (OR = 0.61, 95%
CI = 0.22 to 1.68, P = 0.34; Table 1), but lacking statistical
significance.
The haplotype distribution and corresponding posterior prob-
abilities are shown in Table 2. Since every mean posterior
probability was higher than 0.9, only the most likely haplotypes
were used to evaluate the association with breast cancer risk.
Haplotype analysis showed a nonsignificant inverse associa-
tion of the haplotype 1059C-1234G-1347_1352--3406A
with breast cancer risk (age-adjusted OR = 0.63, 95% CI =
0.23 to 1.75, P  = 0.38; Table 2). The distribution of the
remaining haplotypes between breast cancer patients and
controls was similar, indicating no significant effect with
regard to breast cancer risk. Given our sample size, we had a
90% power to detect an odds ratio of 1.65 (D353E), 1.76
(G412S), and 1.66 (K1136Q), respectively [16]. Contrary to
standard case-control association studies, this study com-
prised predominantly cases selected for family history of
breast cancer. The use of unselected cases would have
required at least twice the sample size to achieve the same
power as in the present study [17,18]. The numbers of cases
within the risk groups A1 to E were too low to be studied
separately, as the power in these subgroups would have been
limited. In addition to the results of this study, one cannot
exclude the possibility that common 53BP1 SNPs may affect
breast cancer risk. Regulatory polymorphisms, for example
polymorphisms that reside in promotor or noncoding regions,
have been shown to modify gene transcription, mRNA stability,
and processing efficiency, as well as DNA methylation
[19,20].
Conclusion
The three known 53BP1 SNPs – D353E, G412S, and
K1136Q – lacked association with breast cancer risk. How-
ever, we detected a novel, very rare 6bp deletion,
1347_1352delTATCCC, that showed a statistically nonsignif-
icant inverse association with breast cancer risk. Concerning
the latter, a much larger study cohort is required to verify any
putative significant effect. Additionally, it would be valuable to
investigate a possible functional effect of this 53BP1 deletion
and its impact on other cancers.
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